Byetta Added to Type 2 Regimens Improves Control


By: Daniel Trecroci

A recent study compared the effect of adding exenatide(Byetta) or insulin glargine (Lantus) to type 2 patients’treatment regimens. The type 2s previously had been takingmetformin and a sulfonylurea with little success.

According to the researchers, patients taking Byetta atdosages of 10 micrograms twice daily achieved reductions inglucose measures similar to those of patients taking Lantus.

“[Byetta] reduced postprandial glucose excursions morethan insulin glargine, while insulin glargine reduced fastingglucose concentrations more than [Byetta],” write theresearchers.

Byetta patients also lost an average of 5 pounds, whilepatients on Lantus gained an average of 4 pounds. Rates ofsymptomatic hypoglycemia were similar between treatmentgroups.

The most common adverse event for Byetta users wasnausea, which was experienced by 57 percent of theparticipants. Six percent of Byetta participants discontinuedits use due to nausea.

Annals of Internal Medicine, October 18, 2005



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.